Novel in Situ Gel Drug Delivery System for Breast Cancer Treatment
Abstract
The rationale of this study was to utilize the overproduction of mucin in cancerous cells as a drug targeting strategy to develop a safe and effective delivery system for taxol. Since the chemotherapeutic agents do not discriminate cancer cells and normal tissue, highly effective cancer treatment agents such as taxol cause major toxicity to normal tissue. This toxicity can be fatal if not prevented. The hypothesis for this project was a mucoadhesive in situ gel delivery system containing paclitaxel can be targeted to the cancerous cells where MUCl gene is overexpressed as compared to normal cells and substantially reduce its toxicity to normal cells. The primary objective of this investigation is to develop a sustained release novel in situ gel delivery system for the targeted local delivery of taxol. The delivery system was designed so that when injected close to the site of tumor, at the biological pH (7.4), the ionic polymer used in the delivery system would deprotonate and turn into an instant gel at the site of injection. This will provide a sustained release of paclitaxel (PIX) from the gel at and around the site of cancer while the systemic drug concentration will be negligible. The specific aims of this study are: 1) formulation, and physicochemical characterization of the in situ gel delivery system, and 2) evaluation of the effectiveness of the targeted local in situ gel delivery system verses the systemic delivery and determination of the local tissue and organ toxicity of the delivery system.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2007
- Accession Number
- ADA474685
Entities
People
- Alekha K. Dash
Organizations
- Creighton University